Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in adults: Genotypes 1, 2, 3, 4, 5, and 6. Patients with or without cirrhosis (compensated). Patients coinfected with HIV-1.

Dosage and administration

Dosage: One tablet taken orally once daily. Treatment Duration: 12 Weeks: Standard duration for non-cirrhotic patients. 24 Weeks: May be required for patients with decompensated cirrhosis (often combined with Ribavirin). ⚠️ Administration: Swallow the tablet whole. Do not crush or chew due to bitter taste. Can be taken with or without food.

Side effects are generally mild and manageable: Fatigue and Headache. Nausea. HBV Reactivation Warning: Hepatitis B virus reactivation has been reported in HCV/HBV coinfected patients. Screening for HBV is mandatory prior to therapy.

Sofokast-Plus — Sofosbuvir 400 mg + 60 mg, 28 product-page.units_short, Aprazer

100% original product

Active ingredient

Sofosbuvir Daclatasvir

Manufacturer

Aprazer

Dosage 400 mg + 60 mg

Dosage form Tablets

Tablets per pack 28

Sofokast-Plus (Sofosbuvir 400 mg + Daclatasvir 60 mg)

Name: Sofokast-Plus
Brand: Aprazer
SKU: PROD-48
Price: 3298 UAH
Availability: InStock

3298₴ ~~3782₴~~ -13%

Sofokast-Plus is a fixed-dose combination antiviral for the treatment of Hepatitis C. Active ingredients: Sofosbuvir (400 mg) + Daclatasvir (60 mg).

Manufacturer: Aprazer Healthcare (India).

Why "Pan-Genotypic"?

Unlike older therapies, this combination works against ALL Hepatitis C genotypes (1 through 6). It is the preferred "universal cure" recommended by the EASL and AASLD guidelines, especially for Genotype 3, which is harder to treat.

✅ Success Rate: Offers a cure rate of over 95-98% with a standard 12-week course.

Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in adults:

Genotypes 1, 2, 3, 4, 5, and 6.
Patients with or without cirrhosis (compensated).
Patients coinfected with HIV-1.

Dosage: One tablet taken orally once daily.

Treatment Duration:

12 Weeks: Standard duration for non-cirrhotic patients.
24 Weeks: May be required for patients with decompensated cirrhosis (often combined with Ribavirin).

⚠️ Administration: Swallow the tablet whole. Do not crush or chew due to bitter taste. Can be taken with or without food.

🚫 CRITICAL INTERACTION: AMIODARONE.

Co-administration with Amiodarone is contraindicated due to the risk of severe symptomatic bradycardia (heart slowing) or fatal cardiac arrest.

Other Contraindications:

Pregnancy and breastfeeding.
Strong inducers of P-gp (e.g., Rifampin, St. John's Wort, Carbamazepine) – they reduce the drug's effectiveness.

Side effects are generally mild and manageable:

Fatigue and Headache.
Nausea.
HBV Reactivation Warning: Hepatitis B virus reactivation has been reported in HCV/HBV coinfected patients. Screening for HBV is mandatory prior to therapy.